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STATE-OF-THE-ART PAPERS STATE-OF-THE-ART PAPERSInﬂammation, Atherosclerosis, and Statins 2491Dimitris Tousoulis, Costas Psarros, Michael Demosthenous, Rikhil Patel, Charalambos Antoniades,
Christodoulos Stefanadis
Tousoulis and colleagues examine the molecular pathways through which statins exert their
anti-inﬂammatory effects. Statins exert their anti-inﬂammatory effects on the vascular wall
through a variety of molecular pathways of the innate and adaptive immune system, their
impact on the circulating levels of proinﬂammatory cytokines, and their effect on the
adhesion molecules. By inhibiting the mevalonate pathway and isoprenoid formation, statins
increase nitric oxide bioavailability and improve the vascular and myocardial redox state. The
authors review the clinical trial data that support a beneﬁcial effect of statins beyond
cholesterol lowering.STATE-OF-THE-ART PAPERSClinical Relevance of Adenosine-Mediated Effects of Ticagrelor 2503Marco Cattaneo, Rainer Schulz, Sven Nylander
Cattaneo and colleagues review the experimental and clinical evidence that ticagrelor
increases the half-life and plasma concentration of adenosine. The effect is mediated
by inhibition of the adenosine transporter, ENT1, providing protection of adenosine
from intracellular metabolism. This increases the concentration and biological activity
of adenosine, particularly at sites of ischemia and tissue injury where it is formed.(continued on page A-29)
JUNE 17, 2014 (continued)CLINICAL RESEARCHA-29INTERVENTIONAL CARDIOLOGYPathology of Early Stent Thrombosis 2510
Masataka Nakano, Kazuyuki Yahagi, Fumiyuki Otsuka, Kenichi Sakakura, Aloke V. Finn,
Robert Kutys, Elena Ladich, David R. Fowler, Michael Joner, Renu Virmani
Nakano and colleagues interrogated their autopsy registry to investigate the histopathological
features of early stent thrombosis (ST). A total of 67 stented coronary lesions were included
from 59 patients who initially presented with an acute coronary syndrome and subsequently
died within 30 days. Early ST was dependent on the underlying plaque morphology and
thrombus burden. Multivariate analysis revealed that maximum depth of strut penetration,
% strut with medial tear, and % struts with incomplete apposition were the primary indicators
of early ST. The current autopsy study highlights the impact of thrombus burden and
suboptimal stent implantation in unstable lesions as a trigger of early ST.
Editorial Comment: Stephan Windecker, Crochan J. O’Sullivan, p. 2521INTERVENTIONAL CARDIOLOGYSex-Related Outcomes for PAD Intervention 2525
Elizabeth A. Jackson, Khan Munir, Theodore Schreiber, Jeffrey R. Rubin, Robert Cuff,
Katherine A. Gallagher, Peter K. Henke, Hitinder S. Gurm, P. Michael Grossman
Jackson and colleagues used a large registry to examine sex-related differences in outcomes
related to percutaneous peripheral vascular interventions (PVI) for the treatment of peripheral
arterial disease (PAD). Compared with men, women were older and more likely to have
multilevel disease and critical limb ischemia. In a propensity-matched analysis, female sex was
associated with higher rates of vascular complications, transfusions, and embolism. No
differences were observed for in-hospital death, myocardial infarction, or stroke/transient
ischemic attack. Women represent a signiﬁcant proportion of patients undergoing lower
extremity PVI, have more severe and complex disease process, and are at increased risk for
adverse outcomes.(continued on page A-30)
JUNE 17, 2014 (continued) A-30CARDIOMETABOLIC RISKAnti-PCSK9 Antibody Monotherapy for Hypercholesterolemia 2531
Michael J. Koren, Pernille Lundqvist, Michael Bolognese, Joel M. Neutel,
Maria Laura Monsalvo, Jingyuan Yang, Jae B. Kim, Rob Scott, Scott M. Wasserman,
Harold Bays, for the MENDEL-2 Investigators
The MENDEL-2 (Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C
in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2) trial
compared biweekly and monthly evolocumab with placebo and oral ezetimibe in patients
with hypercholesterolemia. Evolocumab is a fully human monoclonal antibody against
proprotein convertase subtilisin/kexin type 9 (PCSK9). A total of 614 patients were
randomized and dosed. Evolocumab treatment reduced low-density lipoprotein cholesterol
(LDL-C) from baseline, on average, 55% to 57% more than placebo and 38% to 40% more
than ezetimibe (p < 0.001 for all comparisons). Treatment-emergent adverse events (AEs),
muscle-related AEs, and laboratory abnormalities were comparable across treatment groups.
In the largest monotherapy trial using a PCSK9 inhibitor to date, evolocumab yielded
signiﬁcant LDL-C reductions compared with placebo or ezetimibe and was well tolerated
in hypercholesterolemic patients.CARDIOMETABOLIC RISKAnti-PCSK9 Antibody Lowers Cholesterol in Patients With Statin Intolerance 2541
Erik Stroes, David Colquhoun, David Sullivan, Fernando Civeira, Robert S. Rosenson, Gerald F. Watts,
Eric Bruckert, Leslie Cho, Ricardo Dent, Beat Knusel, Allen Xue, Rob Scott, Scott M. Wasserman,
Michael Rocco, for the GAUSS-2 Investigators
The GAUSS-2 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin
Intolerant Subjects-2) trial evaluated the efﬁcacy and safety of subcutaneous (SC) evolocumab
compared with oral ezetimibe in hypercholesterolemic subjects unable to tolerate effective
statin doses. Evolocumab is a fully human monoclonal antibody to proprotein convertase
subtilisin/kexin type 9 (PCSK9). This 12-week trial randomized subjects to various
combinations of evolocumab or ezetimibe, both with placebo. Evolocumab reduced low-density
lipoprotein cholesterol from baseline by 53% to 56%, with corresponding treatment
differences versus ezetimibe of 37% to 39%. Potential muscle adverse events (AEs) occurred
in 12% of evolocumab and 23% of ezetimibe patients. Treatment-emergent AEs and hepatic
laboratory abnormalities were comparable across treatment groups. Evolocumab appears to be
a promising therapy for patients with elevated cholesterol who are statin intolerant.(continued on page A-31)
JUNE 17, 2014 (continued) A-31HEART FAILURESimultaneous Adrenal and Cardiac GPCR-Gbg Inhibition
Halts HF Progression in Animal Model
2549Fadia A. Kamal, Deanne M. Mickelsen, Katherine M. Wegman, Joshua G. Travers, Jacob Moalem,
Stephen R. Hammes, Alan V. Smrcka, Burns C. Blaxall
Chronically elevated sympathetic nervous system activity, as seen in heart failure (HF), causes
pathological desensitization of beta-adrenergic receptors (b-AR). Kamal and colleagues
tested the possible therapeutic effects of small-molecule Gßg inhibition in an HF model,
transverse aortic constriction (TAC). Mice treated with gallein following TAC had improved
survival and cardiac function, and had attenuated cardiac remodeling compared with placebo-
treated animals. Gallein restored b-AR membrane density in cardiomyocytes, attenuated
Gbg-mediated GRK2-PI3Kg membrane recruitment, and reduced Akt and GSK-3b
phosphorylation. Gallein also reduced catecholamine production in isolated mouse adrenal
glands. These data suggest that Gbg inhibition may improve HF outcomes by normalizing
pathological adrenergic/Gbg signaling in both the heart and the adrenal glands.
Editorial Comment: Jennifer L. Hall, Timothy D. O’Connell, Gary S. Francis, p. 2558HEART RHYTHM6-Min Walk Predicts Treatment Effects of Amiodarone or ICD 2560
Daniel P. Fishbein, Anne S. Hellkamp, Daniel B. Mark, Mary Norine Walsh, Jeanne E. Poole,
Jill Anderson, George Johnson, Kerry L. Lee, Gust H. Bardy, for the SCD-HeFT Investigators
In the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial), patients with New York
Heart Association (NYHA) functional class III symptoms did not beneﬁt from implantable
cardioverter-deﬁbrillator (ICD) therapy and appeared to be harmed by amiodarone, whereas
NYHA functional class II patients beneﬁted from ICD. Fishbein and colleagues postulated
that a more objective measure of functional capacity, such as 6-min walk (6MW) distance,
might provide a better risk stratiﬁcation than NYHA functional class. A 6MW test was
performed before randomization in a subset of SCD-HeFT patients. ICD therapy improved
outcomes compared with placebo for the higher 2 tertiles of 6MW distance, but not the
lowest tertile. Similar results were seen for amiodarone, although the lowest tertile of patients
appeared to be harmed by amiodarone. A baseline 6MW distance <288 m identiﬁed a
subgroup of SCD-HeFT patients who were harmed by amiodarone therapy and did not
beneﬁt from ICD.(continued on page A-32)
JUNE 17, 2014 (continued) A-32BIOMARKERSUndetectable hs-cTnT Level in the ED 2569
Nadia Bandstein, Rickard Ljung, Magnus Johansson, Martin J. Holzmann
Bandstein and colleagues reviewed 2 years of emergency department (ED) visits to evaluate
whether an undetectable (<5 ng/l) high-sensitivity cardiac troponin T (hs-cTnT) level and
an electrocardiogram (ECG) without signs of ischemia can rule out myocardial infarction
(MI) at ED arrival. Of nearly 15,000 patients presenting with chest pain, 61% had an initial
hs-cTnT of <5 ng/l. During 30 days of follow-up, 0.44% of patients with undetectable
hs-cTnT had an MI, and only one-third of these patients had no ischemic ECG changes on
arrival. The negative predictive value for MI within 30 days in patients with undetectable
hs-cTnT and no ischemic ECG changes was 99.8%; the negative predictive value for
death was 100%. These results suggest that patients with chest pain who have an initial
hs-cTnT level of <5 ng/l and no signs of ischemia on ECG can be safely discharged
directly from the ED.
